Proportional constrained longitudinal data analysis models for clinical trials in sporadic Alzheimer's disease

Alzheimers Dement (N Y). 2022 Apr 5;8(1):e12286. doi: 10.1002/trc2.12286. eCollection 2022.

Abstract

Introduction: Clinical trials for sporadic Alzheimer's disease generally use mixed models for repeated measures (MMRM) or, to a lesser degree, constrained longitudinal data analysis models (cLDA) as the analysis model with time since baseline as a categorical variable. Inferences using MMRM/cLDA focus on the between-group contrast at the pre-determined, end-of-study assessments, thus are less efficient (eg, less power).

Methods: The proportional cLDA (PcLDA) and proportional MMRM (pMMRM) with time as a categorical variable are proposed to use all the post-baseline data without the linearity assumption on disease progression.

Results: Compared with the traditional cLDA/MMRM models, PcLDA or pMMRM lead to greater gain in power (up to 20% to 30%) while maintaining type I error control.

Discussion: The PcLDA framework offers a variety of possibilities to model longitudinal data such as proportional MMRM (pMMRM) and two-part pMMRM which can model heterogeneous cohorts more efficiently and model co-primary endpoints simultaneously.

Keywords: Alzheimer's disease; MMRM; proportional MMRM (pMMRM); proportional constrained longitudinal data analysis model (PcLDA); proportional treatment effect.